Skip to main navigation Skip to search Skip to main content

Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

  • J Ying
  • , Z Gao
  • , H Li
  • , G Srivastava
  • , Paul Murray
  • , HK Goh
  • , CY Lim
  • , Y Wang
  • , T Marafioti
  • , DY Mason
  • , RF Ambinder
  • , ATC Chan
  • , Q Tao

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.
Original languageEnglish
Pages (from-to)829-832
Number of pages4
JournalBritish Journal of Haematology
Volume136
Issue number6
DOIs
Publication statusPublished - 1 Mar 2007

Keywords

  • methylation
  • tumour suppressor gene
  • biomarker
  • PCDH10
  • lymphoma

Fingerprint

Dive into the research topics of 'Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies'. Together they form a unique fingerprint.

Cite this